Kyowa Kirin Co., Ltd.

Kyowa Kirin Co., Ltd. Estimates – TSE:4151
TradingView · 24 Oct 2026
How Three Year XLH Data Will Impact Kyowa Kirin Stock
Simply Wall Street · 24 Oct 2026
Kyowa Kirin (TSE:4151) Posts New XLH Data, Is The Discount Too Wide?
Simply Wall Street · 20 Oct 2026
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Pharmaceutical Technology · 30 Sep 2026
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
BioSpace · 29 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.